The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Tepezza Amgen Australia Pty Ltd
Product name
Tepezza
Sponsor
Accepted date
Apr-2024
Active ingredients
teprotumumab
Proposed indication
For the treatment of Thyroid Eye Disease (TED).
Application type
A (new medicine)
Publication date
Apr-2024
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available.